KOO vs. RENX, FUM, SCLP, CREO, DXRX, ANCR, BVC, EAH, SPEC, and AGY
Should you be buying Kooth stock or one of its competitors? The main competitors of Kooth include Renalytix (RENX), Futura Medical (FUM), Scancell (SCLP), Creo Medical Group (CREO), Diaceutics (DXRX), Animalcare Group (ANCR), BATM Advanced Communications (BVC), ECO Animal Health Group (EAH), INSPECS Group (SPEC), and Allergy Therapeutics (AGY). These companies are all part of the "medical" sector.
Renalytix (LON:RENX) and Kooth (LON:KOO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, community ranking, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
21.4% of Renalytix shares are owned by institutional investors. Comparatively, 80.0% of Kooth shares are owned by institutional investors. 31.6% of Renalytix shares are owned by company insiders. Comparatively, 11.3% of Kooth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Renalytix has a net margin of 0.00% compared to Renalytix's net margin of -0.51%. Renalytix's return on equity of -1.08% beat Kooth's return on equity.
Renalytix received 16 more outperform votes than Kooth when rated by MarketBeat users. However, 87.50% of users gave Kooth an outperform vote while only 74.19% of users gave Renalytix an outperform vote.
In the previous week, Kooth had 3 more articles in the media than Renalytix. MarketBeat recorded 3 mentions for Kooth and 0 mentions for Renalytix. Renalytix's average media sentiment score of 0.82 beat Kooth's score of 0.00 indicating that Kooth is being referred to more favorably in the news media.
Kooth has higher revenue and earnings than Renalytix.
Kooth has a consensus target price of GBX 580, suggesting a potential upside of 92.05%. Given Renalytix's higher probable upside, analysts clearly believe Kooth is more favorable than Renalytix.
Renalytix has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Comparatively, Kooth has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
Summary
Kooth beats Renalytix on 9 of the 15 factors compared between the two stocks.
Get Kooth News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
